Corin Group's FDA Approval for the Cormet(TM) Hip Resurfacing System Paves Way for Stryker to Educate and Advance the MarketKALAMAZOO, Mich., July 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Stryker Corporation
(NYSE: SYK) announced that it will begin marketing Corin Group PLC's
(LSE: CRG) Cormet Hip Resurfacing System as early as the third quarter of this
year. This follows today's FDA approval of Cormet and is predicated on a
comprehensive surgeon education protocol developed by Stryker and Corin, in
cooperation with the FDA, emphasizing patient selection criteria to promote
successful outcomes. Stryker's Orthopaedics division previously secured an
exclusive 10-year agreement to market and distribute the Cormet Hip
Resurfacing System in the United States.
Interest in hip resurfacing procedures is on the rise globally due to the
bone conserving nature of the procedure and anticipated potential benefits
related to post-operative activities and range of motion. In these procedures,
surgeons replace the acetabulum in much the same way as a conventional total
hip but the femoral head is resurfaced rather than removed. Hip resurfacing
is viewed by many surgeons as an alternative to traditional hip replacements
to help patients indicated for the technology return to their active
Corin is the first manufacturer to receive FDA approval based on a U.S.
prospective, multi-center, clinical study that highlights the importance of
appropriate patient selection and surgeon education for this emerging
technology segment. The results support the need for surgeons to focus on
several key anatomic and physiologic factors when determining if resurfacing
is the right option for a patient.
"Hip resurfacing offers the right patient a more conservative, bone
preserving procedure than traditional hip replacement. The anatomic nature of
these devices enables certain younger, more active patients to get back to the
activities that are important to them," said, Bernard Stulberg, M.D., Director,
Cleveland Center for Joint Reconstruction. He added, "the dialogue between
surgeon and patient will be more critical than ever in determining which
anatomic option is right for the patient."
Stryker is committed to providing surgeons with the appropriate patient
selection information, tools and training to drive positive patient outcomes.
As such, a comprehensive surgeon education protocol has been developed in
cooperation with Corin and the FDA to enable U.S. surgeons to perform the
technique properly and with confidence.
"Resurfacing is an important extension of our hip portfolio which focuses
on providing personalized solutions based on the unique needs of a diverse
patient population. Stryker remains dedicated to introducing technological
advancements that help improve patient outcomes," said Mike Mogul, President,
Ian Paling, CEO of Corin, added, "We're delighted to partner with Stryker
to bring the Cormet Hip Resurfacing System to the U.S. market. Their market
leadership and unwavering commitment to providing surgeons and patients in the
U.S. with the proper training and education coupled with our experience in hip
resurfacing will enable the right patients to benefit from this emerging
Stryker plans to initiate surgeon training programs in the third quarter
of 2007. Corin will begin supplying product in conjunction with the schedule
for these programs.
Stryker Corporation is one of the world's leading medical technology
companies with the most broadly based range of products in orthopaedics and a
significant presence in other medical specialties. Stryker works with
respected medical professionals to help people lead more active and more
satisfying lives. The Company's products include implants used in joint
replacement, trauma, craniomaxillofacial and spinal surgeries; biologics;
surgical, neurologic, ear, nose & throat and interventional pain equipment;
and endoscopic, surgical navigation, communications and digital imaging
systems; as well as patient handling and emergency medical equipment. For more
information about Stryker, please visit the company web site at
SOURCE Stryker Corporation
Katherine A. Owen, Vice President, Strategy and Investor Relations of Stryker